Omnicell (OMCL) 10-Q 7 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Entity [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926,326
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		35,906,254
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 88,028	$ 125,888
Accounts receivable, net of allowances of $1,640 and $1,279, respectively	117,307	82,763
Inventories, net	46,027	31,554
Prepaid expenses	15,401	23,518
Deferred tax assets	12,490	12,446
Other current assets	6,071	7,215
Total current assets	285,324	283,384
Property and equipment, net	34,772	36,178
Long-term net investment in sales-type leases	10,208	10,848
Goodwill	149,654	122,720
Intangible assets, net	94,285	82,667
Long-term deferred tax assets	1,397	1,144
Other long-term assets	25,382	23,273
Total assets	601,022	560,214
Current liabilities:
Accounts payable	26,085	19,432
Accrued compensation	18,573	19,874
Accrued liabilities	33,419	19,299
Deferred service revenue	23,527	25,167
Deferred gross profit	36,671	28,558
Total current liabilities	138,275	112,330
Long-term deferred service revenue	19,056	20,308
Long-term deferred tax liabilities	32,723	30,454
Other long-term liabilities	11,620	7,024
Total liabilities	$ 201,674	$ 170,116
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 100,000 shares authorized; 44,252 and 43,540 shares issued; 35,851 and 35,816 shares outstanding, respectively, respectively	$ 44	$ 43
Treasury stock, at cost, 8,401 and 7,721 shares outstanding	(160,074)	(135,053)
Additional paid-in capital	475,209	457,436
Retained earnings	84,102	69,033
Accumulated other comprehensive income (loss)	67	(1,361)
Total stockholders’ equity	399,348	390,098
Total liabilities and stockholders’ equity	$ 601,022	$ 560,214

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowances	$ 1,640	$ 1,279
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares, Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	44,252,000	43,540,000
Common Stock, Shares, Outstanding	35,851,000	35,816,000
Treasury Stock, Shares	8,401,000	7,721,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Product	$ 89,154	$ 85,244	$ 183,263	$ 167,824
Services and other revenues	23,634	19,808	45,746	38,992
Total revenues	112,788	105,052	229,009	206,816
Cost of revenues:
Cost of product revenues	46,203	41,003	91,619	79,903
Cost of services and other revenues	9,123	8,009	18,243	16,378
Total cost of revenues	55,326	49,012	109,862	96,281
Gross profit	57,462	56,040	119,147	110,535
Operating expenses:
Research and development	8,746	6,471	16,765	12,592
Selling, general and administrative	39,735	37,011	83,022	75,431
Gain on business combination	(3,443)	0	(3,443)	0
Total operating expenses	45,038	43,482	96,344	88,023
Income from operations	12,424	12,558	22,803	22,512
Interest and other (expense), net	(472)	(40)	(989)	(296)
Income before provision for income taxes	11,952	12,518	21,814	22,216
Provision for income taxes	3,201	4,729	6,745	8,233
Net income	$ 8,751	$ 7,789	$ 15,069	$ 13,983
Net income per share:
Basic (in dollars per share)	$ 0.24	$ 0.22	$ 0.42	$ 0.39
Diluted (in dollars per share)	$ 0.24	$ 0.21	$ 0.41	$ 0.38
Weighted-average shares outstanding:
Basic (in shares)	36,120	35,661	36,072	35,451
Diluted (in shares)	37,030	36,618	36,987	36,478

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 8,751	$ 7,789	$ 15,069	$ 13,983
Other comprehensive income (loss), net of reclassification adjustments:
Foreign currency translation adjustments	2,305	87	1,428	119
Other comprehensive income (loss)	2,305	87	1,428	119
Comprehensive income	$ 11,056	$ 7,876	$ 16,497	$ 14,102

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Activities
Net income	$ 15,069	$ 13,983
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,977	9,391
Gain (loss) on disposal of fixed assets	(5)	202
Gain on business combination	(3,443)	0
Provision for receivable allowance	480	436
Share-based compensation expense	7,301	5,449
Income tax benefits from employee stock plans	3,087	3,058
Excess tax benefits from employee stock plans	(3,159)	(3,326)
Provision for excess and obsolete inventories	168	250
Deferred income taxes	(1,717)	860
Changes in operating assets and liabilities:
Accounts receivable, net	(27,676)	(24,408)
Inventories	(9,633)	(335)
Prepaid expenses	8,234	2,144
Other current assets	1,507	1,602
Net investment in sales-type leases	353	622
Other long-term assets	64	228
Accounts payable	1,364	2,494
Accrued compensation	(1,654)	(3,910)
Accrued liabilities	5,752	2,424
Deferred service revenue	(2,892)	2,640
Deferred gross profit	6,008	10,788
Other long-term liabilities	(995)	829
Net cash provided by operating activities	10,190	25,421
Investing Activities
Acquisition of intangible assets, intellectual property and patents	(225)	(191)
Software development for external use	(6,127)	(5,507)
Purchases of property and equipment	(3,764)	(7,335)
Business acquisitions, net of cash acquired	(23,625)	0
Net cash used in investing activities	(33,741)	(13,033)
Financing Activities
Proceeds from issuances under stock-based compensation plans	9,432	11,813
Employees' taxes paid related to restricted stock units	(2,046)	(1,729)
Common stock repurchases	(25,021)	(4,069)
Excess tax benefits from employee stock plans	3,159	3,326
Net cash (used) provided by financing activities	(14,476)	9,341
Effect of exchange rate changes on cash and cash equivalents	167	119
Net (decrease) increase in cash and cash equivalents	(37,860)	21,848
Cash and cash equivalents at beginning of period	125,888	104,531
Cash and cash equivalents at end of period	88,028	126,379
Supplemental cash flow information
Cash paid for interest	80	0
Cash paid for taxes, net of refunds	3,620	1,723
Supplemental disclosing of non-cash investing activities
Purchase of property and equipment	524	70
Non-cash activity Business acquisition	$ 9,197	$ 0

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication, supply control systems and medication adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Canada. "Omnicell," "our," "us," "we," or the "Company" collectively refer to Omnicell, Inc. and its subsidiaries. Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of June 30, 2015 and December 31, 2014 , the results of their operations, comprehensive income and cash flows for the three and six months ended June 30, 2015 and June 30, 2014 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in our annual report on Form 10-K for the year ended December 31, 2014 . Our results of operations, comprehensive income and cash flows for the three and six months ended June 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015 , or for any future period. Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On April 21, 2015, we completed the acquisition of Mach4 Automatisierungstechnik GmbH (“Mach4”), a privately held German limited liability company with registered office in Bochum, Germany. On April 30, 2015, we acquired the 85% of the issued and outstanding ordinary shares of Avantec Healthcare Limited (“Avantec”) not already held by Omnicell. Omnicell previously had a 15% interest in Avantec. The consolidated financial statements include the results of operations of Mach4 and Avantec commencing as of their respective acquisition dates. Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, accounts receivable and notes receivable (net investment in sales-type leases), valuation of goodwill, purchased intangibles and long-lived assets, and accounting for income taxes. Segment reporting change As previously disclosed, since the first quarter of 2015, we modified the segment presentation to reflect the changes in how our Chief Operating Decision Maker (“CODM”) reviews the segments and the overall business. This change does not impact previously reported Condensed Consolidated Financial Statements. See Note 14, Segment Information, for additional information on our segment reporting change. Our CODM is our Chief Executive Officer. With the increase in completed acquisitions in the last two years , our CODM changed how the financial information was reviewed to exclude general corporate-level costs that are not specific to either of the reporting segments when evaluating the operating results of each segment. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The historical information presented has been retrospectively adjusted to reflect the modified segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations, excluding certain costs which are managed separately at the corporate level. We enhanced our segment reporting structure to match our operating structure based on how our CODM views the business and allocates resources, beginning in the first quarter of 2015. Concentration of credit risk Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there were no customers that accounted for more than 10% of our accounts receivable as of June 30, 2015 and December 31, 2014 . We believe that we have no significant concentrations of credit risk as of June 30, 2015 . Significant accounting policies There have been no material changes in our significant accounting policies for the three and six months ended June 30, 2015 , as compared to the significant accounting policies described in our annual report on Form 10-K for the year ended December 31, 2014 . Recently issued authoritative guidance In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which provides new guidance on the recognition of revenue and states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard will be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted, however, in July 2015, the FASB voted to approve deferring the effective date by one year (i.e., interim and annual reporting periods beginning after December 15, 2017). Early adoption is permitted, but not before the original effective date (i.e., interim and annual reporting periods beginning after December 15, 2016). For financial reporting purposes, the standard allows for either full retrospective adoption, meaning the standard is applied to all of the periods presented, or modified retrospective adoption, meaning the standard is applied only to the most current period presented in the financial statements with the cumulative effect of initially applying the standard recognized at the date of initial application. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. There was no other recently issued authoritative guidance that has a material impact on our Condensed Consolidated Financial Statements through the reporting date.

Net Income Per Share

Net Income Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted-average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since the impact is anti-dilutive, these shares were excluded from the calculations of diluted net income per share. The calculation of basic and diluted net income per share is as follows: Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 (In thousands, except per share data) Net income $ 8,751 $ 7,789 $ 15,069 $ 13,983 Weighted-average shares outstanding — basic 36,120 35,661 36,072 35,451 Dilutive effect of employee stock plans 910 957 915 1,027 Weighted-average shares outstanding — diluted 37,030 36,618 36,987 36,478 Net income per share — basic $ 0.24 $ 0.22 $ 0.42 $ 0.39 Net income per share — diluted $ 0.24 $ 0.21 $ 0.41 $ 0.38 Anti-dilutive weighted-average shares related to stock award plans 377 353 356 1,347

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents as of June 30, 2015 and December 31, 2014 includes the following significant asset investment class: Cash equivalents. Cash equivalents consist of money market funds which have original maturities of three months or less, and therefore the carrying amount is a reasonable estimate of fair value due to the short duration to maturity. The following table summarizes our assets measured at fair value on a recurring basis using Level 1 inputs within the fair value hierarchy: June 30, December 31, (In thousands) Cash $ 27,925 $ 61,311 Money market fund 60,103 64,577 Total cash and cash equivalents $ 88,028 $ 125,888 Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1. Cash equivalents are valued primarily using quoted market prices utilizing market observable inputs. In addition, foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. The Level 3 valuation inputs include the Company’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation. We did not hold any Level 3 assets or liabilities as of June 30, 2015 and December 31, 2014 . There have been no transfers between fair value measurement levels during the three and six months ended June 30, 2015 . The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of June 30, 2015 : Level 1 Level 2 Total (In thousands) Money market funds $ 60,103 $ — $ 60,103 Total financial assets $ 60,103 $ — $ 60,103 Derivative contracts $ — $ 92 $ 92 Total financial liabilities $ — $ 92 $ 92 The following table represents the fair value hierarchy of the Company’s financial asset measured at fair value as of December 31, 2014 : Level 1 Level 2 Total (In thousands) Money market fund $ 64,577 $ — $ 64,577 Total financial assets $ 64,577 $ — $ 64,577 Net investment in sales-type leases. The carrying amount of our sales-type lease receivables is a reasonable estimate of fair value as the unearned interest income is immaterial. Foreign Currency Risk Management We operate in foreign countries, which exposes us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound. In order to manage foreign currency risk, we enter into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Condensed Consolidated Balance Sheets. The derivative instruments we use to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Condensed Consolidated Statements of Operations. We do not enter into derivative contracts for trading purposes. The aggregate notional amounts of our outstanding foreign exchange contracts as of June 30, 2015 were $2.2 million . The aggregate fair value of these outstanding foreign exchange contracts as of June 30, 2015 were $0.1 million . We did not have any outstanding foreign exchange contracts as of December 31, 2014.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components June 30, December 31, (In thousands) Inventories: Raw materials $ 10,725 $ 8,254 Work in process 2,554 64 Finished goods 32,748 23,236 Total inventories, net $ 46,027 $ 31,554 Property and Equipment: Equipment $ 43,717 $ 42,829 Furniture and fixtures 5,895 5,689 Leasehold improvements 8,991 8,701 Purchased software 29,729 28,920 Construction in progress 3,982 1,538 92,314 87,677 Accumulated depreciation and amortization (57,542 ) (51,499 ) Total Property and equipment, net $ 34,772 $ 36,178 Other long term assets: Capitalized software, net $ 23,066 $ 19,643 Other assets 2,316 3,630 Total Other long term assets, net $ 25,382 $ 23,273 Accrued liabilities: Rebates and lease buyouts $ 7,253 $ 6,512 Advance payments from customers 7,840 4,834 Group purchasing organization fees 3,007 3,475 Taxes payable 3,488 2,181 Other Accrued liabilities 11,831 2,297 Total Accrued liabilities $ 33,419 $ 19,299

Net Investment in Sales-Type Le

Net Investment in Sales-Type Leases	6 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases The terms of our sales-type leases are generally up to five years in length. Sales-type lease receivables are collateralized by the underlying equipment. Net investment in sales-type leases consists of the following components: June 30, December 31, (In thousands) Net minimum lease payments to be received $ 16,674 $ 17,616 Less: unearned interest income portion (1,118 ) (1,131 ) Net investment in sales-type leases 15,556 16,485 Less: short-term portion (5,348 ) (5,637 ) Long-term net investment in sales-type leases $ 10,208 $ 10,848 We evaluate our sales-type leases individually and collectively for impairment, and recorded no collective allowance for credit losses as of June 30, 2015 and $0.2 million as of December 31, 2014 . The minimum lease payments under sales-type leases are as follows: June 30, (In thousands) Remainder of 2015 $ 3,147 2016 5,308 2017 4,281 2018 2,652 2019 1,054 Thereafter 232 Total $ 16,674

Business Acquisitions

Business Acquisitions	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions Mach4 Acquisition On April 21, 2015, we completed the acquisition of Mach 4 Automatisierungstechnik GmbH (“Mach4”), a privately held German limited liability company with its registered office in Bochum, Germany pursuant to a share purchase agreement (the “Mach4 Agreement”), under which Omnicell International, Inc., a wholly owned subsidiary of Omnicell Inc., purchased the entire issued share capital of Mach4 (the “Mach4 Acquisition”). Mach4 manufacturers robotic dispensing systems used by retail and hospital pharmacies and the Mach4 acquisition provides Omnicell with a more robust product offering that is intended to be leveraged to create opportunities to sell additional Omnicell medication cabinets. The robotic storage and dispensing product offering provides Omnicell with a solution to better compete for international market share. Pursuant to the terms of the Mach4 Agreement, we paid approximately $17.2 million in cash after adjustments provided for in the Mach4 Agreement, of which $2.7 million was placed in an escrow fund, which will be distributed to Mach4's former stockholders subject to claims that we may make against the escrow fund with respect to indemnification and other claims within 18 months after the closing date of this transaction. Avantec Acquisition On April 30, 2015, we completed the acquisition of Avantec Healthcare Limited (“Avantec”), the privately-held distributor of Omnicell’s products in United Kingdom, pursuant to a share purchase agreement (the “Avantec Agreement”). Pursuant to the Avantec Agreement, we acquired the entire issued and outstanding ordinary shares of Avantec that represented the remaining 85% interest in Avantec (the “Avantec Acquisition”). Omnicell previously had a 15% interest in Avantec. Avantec develops medication and supply automation products that complement our solutions for configurations suited to the United Kingdom marketplace, and has been the exclusive distributor of our medication and supply automation solutions since 2005 in the United Kingdom. Pursuant to the terms of the Avantec Agreement, we agreed to pay $12.0 million in cash (the “Purchase Consideration”) and potential earn-out payments of up to $3.0 million payable after December 31, 2015 and an additional $3.0 million payable after December 31, 2016, based on future bookings. The fair value of these potential earn-out payments as of the acquisition date was $5.6 million . Pursuant to the terms of the Avantec Agreement we retained $1.8 million of the Purchase Consideration to be held to settle any future indemnification claims within 18 months period that we may make following the closing. Prior to the Avantec Acquisition, we accounted for our 15% ownership interest in Avantec as an equity-method investment. The Avantec acquisition-date carrying book value of our previous equity interest was $1.3 million . This transaction was accounted for as a step acquisition, which required us to re-measure our previously held 15% ownership interest to fair value and record the difference between the fair value and carrying value as a gain. The fair value of the equity investment was determined to be $4.7 million that resulted in a gain of $3.4 million that was recorded in operating income in our Condensed Consolidated Statement of Operations in the period ended June 30, 2015. Both of the above acquired companies will be in the Company’s Automation and Analytics segment. We are accounting for both transactions under the acquisition method of accounting in accordance with the provisions of FASB Accounting Standards Codification ("ASC") Topic 805, Business Combinations . Accordingly, the estimated fair value of the consideration transferred to purchase the acquired companies is allocated to the assets acquired and the liabilities assumed based on their respective fair values. We have made significant estimates and assumptions in determining the allocation of the acquisition consideration. The purchase price allocations are subject to certain post-closing working capital adjustments for the acquired current assets and current liabilities of both acquisitions at their respective acquisition dates. The total consideration, and the allocation of consideration to the individual net assets is preliminary, as there are remaining uncertainties to be resolved, including the settlement of the final net working capital adjustment for each. Our preliminary allocation of the total purchase price for each transaction is summarized below: Mach4 Avantec Total (In thousands) Cash $ 397 $ 3,392 $ 3,789 Accounts receivable 3,743 3,607 7,350 Inventory 3,580 1,428 5,008 Deferred tax assets and other current assets 368 89 457 Total current assets 8,088 8,516 16,604 Property and equipment 463 — 463 Intangibles 7,710 6,341 14,051 Goodwill 10,520 15,606 26,126 Other non-current assets 52 — 52 Total assets 26,833 30,463 57,296 Current liabilities 3,684 4,125 7,809 Non-current deferred tax liabilities 2,564 1,269 3,833 Deferred service revenue and gross profit 2,314 928 3,242 Other non-current liabilities 1,056 — 1,056 Total purchase price $ 17,215 $ 24,141 $ 41,356 Total purchase price, net of cash received $ 16,818 $ 20,749 $ 37,567 Identifiable intangible assets Intangible assets acquired and their respective estimated remaining useful lives over which each asset will be amortized are as follows: Mach4 Avantec Fair Value Weighted Fair Value Weighted Average Useful life (In thousands) (In years) (In thousands) (In years) Developed Technology $ 3,290 8 $ — — Trade name 850 6 92 2 Customer relationships 3,570 11-12 5,834 12 Backlog — — 415 2 Total purchased intangible assets $ 7,710 $ 6,341 Developed technology represents completed technology that has reached the technological feasibility and/or is currently offered for sale to Mach4 customers. The fair value is determined based on the relief from royalty method under the income approach, which requires the valuation specialist to estimate a reasonable royalty rate, identify relevant projected revenues and expenses, and select an appropriate discount rate. A royalty rate of 5.0% was used to value the developed technology. The after-tax cash flows were discounted to present value utilizing a 17.5% discount rate, which is based on the our company-wide required return for this acquisition plus a discount of 1.5% to account for the unique riskiness of the asset. The developed technology had a fair value of $3.3 million and had an estimated economic life of eight years based on estimated technological obsolescence and is being amortized on an accelerated basis. Trade name represents the fair value brand recognition that was determined using the relief-from-royalty approach. The fair value is determined based on the relief-from-royalty method under the income approach, which requires the valuation specialist to estimate a reasonable royalty rate, identify relevant projected revenues and expenses, and select an appropriate discount rate. A royalty rate of 1.0% and 2.0% was used to value the trade names of Avantec and Mach4, respectively. The value of trade names of $0.1 million for Avantec is being amortized on straight-line method and $0.9 million for Mach4 is being amortized on an accelerated basis. Customer relationships represent the fair value of future projected revenues that will be derived from the sale of products to existing customers of the acquired company. The fair value of the customer relationships is determined based on the excess earnings method under the income approach that resulted in a value of $3.6 million for Mach4 and $5.8 million for Avantec and has been amortized over their useful lives on accelerated basis. Backlog represents the fair value of sales order backlog as of the valuation date and its fair value is determined based on the excess earnings method under the income approach and is being amortized on straight-line method. Goodwill The goodwill arising from these acquisitions is primarily attributed to sales of future products and services and the assembled workforce. Goodwill is not deductible for tax purposes. Goodwill is not being amortized but is reviewed annually for impairment or more frequently if impairment indicators arise, in accordance with authoritative guidance. The following table presents certain unaudited pro forma information for illustrative purposes only, for fiscal 2015 and fiscal 2014 as if Mach4 and Avantec had been acquired on January 1, 2014. The unaudited estimated pro forma information combines the historical results of Mach4 and Avantec with the Company’s consolidated historical results and includes certain adjustments reflecting the estimated impact of fair value adjustments for the respective periods. The pro forma information is not indicative of what would have occurred had the acquisitions taken place on January 1, 2014. Additionally, the pro forma financial information does not include the impact of possible business model changes between Mach4, Avantec and the Company. The Company expects to achieve further business synergies, as a result of the acquisitions that are not reflected in the pro forma amounts that follow. As a result, actual results will differ from the unaudited pro forma information presented (in thousands, except per share data): Six Months Ended June 30, 2015 2014 (In thousands, except per share data) Pro forma net revenues $ 236,000 $ 220,000 Pro forma net income $ 15,700 $ 14,400 Pro forma net income per share basic $ 0.44 $ 0.41 Pro forma net income per share diluted $ 0.42 $ 0.39

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The changes in the carrying amount of goodwill are as follows: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2014 $ 28,543 $ 94,177 $ 122,720 Goodwill acquired - Mach4 10,520 — 10,520 Goodwill acquired - Avantec 15,606 — 15,606 Foreign currency exchange rate fluctuations 729 79 808 Net balance as of June 30, 2015 $ 55,398 $ 94,256 $ 149,654 Intangible assets, net The carrying amounts of intangibles as of June 30, 2015 are as follows: June 30, 2015 Gross Carrying Amount Accumulated Amortization Foreign Currency Exchange Rate Fluctuations Net Carrying Amount Useful Life (Years) (In thousands, except for years) Customer relationships $ 69,554 $ (9,182 ) $ (94 ) $ 60,278 5 - 30 Acquired technology 30,870 (4,967 ) 122 26,025 3 - 20 Trade names 8,052 (2,012 ) 2 6,042 1 - 12 Patents 1,879 (320 ) — 1,559 2 - 20 Backlog 415 (42 ) 8 381 1.7 Total intangibles assets, net $ 110,770 $ (16,523 ) $ 38 $ 94,285 The carrying amounts of intangibles as of December 31, 2014 are as follows: December 31, 2014 Gross Carrying Amount Accumulated Amortization Foreign currency exchange rate fluctuations Net Carrying Amount Useful Life (Years) Customer relationships $ 60,150 $ (7,596 ) $ (323 ) $ 52,231 5 - 30 Acquired technology 27,580 (4,068 ) — 23,512 3 - 20 Trade names 7,110 (1,559 ) (17 ) 5,534 3 - 12 Patents 1,655 (265 ) — 1,390 2 - 20 Total intangibles assets, net $ 96,495 $ (13,488 ) $ (340 ) $ 82,667 Amortization expense of intangible assets was $1.8 million and $1.1 million for the three months ended June 30, 2015 and June 30, 2014 , respectively, and $3.1 million and $2.2 million for the six months ended June 30, 2015 and June 30, 2014 , respectively. The estimated future amortization expenses for intangible assets are as follows: June 30, (In thousands) Remainder of 2015 $ 3,510 2016 6,599 2017 5,843 2018 5,463 2019 5,297 Thereafter 67,573 Total $ 94,285

Deferred Gross Profit

Deferred Gross Profit	6 Months Ended
	Jun. 30, 2015
Revenue Recognition [Abstract]
Deferred Gross Profit	Deferred Gross Profit Deferred gross profit consists of the following: June 30, December 31, (In thousands) Sales of medication and supply dispensing systems including packaging equipment (1) $ 55,304 $ 36,947 Less: cost of revenues, excluding installation costs (18,633 ) (8,389 ) Total deferred gross profit $ 36,671 $ 28,558 _________________________________________________ (1) Delivered and invoiced, pending installation.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments Lease commitments We lease our buildings under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. The minimum future payments on non-cancelable operating leases are as follows: June 30, (In thousands) Remainder of 2015 $ 3,421 2016 6,557 2017 5,900 2018 5,487 2019 5,490 Thereafter 15,295 Total minimum future lease payments $ 42,150 Purchase obligations We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. These amounts are associated with agreements that are enforceable and legally binding. Our purchase obligations to our contract manufacturers and suppliers within the next year were $25.2 million as of June 30, 2015 .

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Legal Proceedings We are currently involved in various legal proceedings. As required under ASC 450, Contingencies , we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We have not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on our belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses. Pending legal proceedings as of June 30, 2015 are as follows: On September 12, 2014, MV Circuit Design, Inc., an Ohio company ("MV Circuit"), brought an action to correct the inventorship of certain patents owned by Omnicell, as well as related state-law claims against Omnicell in the Northern District of Ohio (Case No. 1:14-cv-02028-DAP) regarding allegations of fraud in the filing and prosecution of U.S. Patent Nos. 8,180,485, 8,773,270, 8,812,153, PCT/US2007/003765, PCT/US2011/063597, and PCT/US2011/0635505 (the “Action”). On November 14, 2014, we filed a Motion to Dismiss the Action. MV Circuit responded on January 29, 2015, and we replied in support of our Motion to Dismiss on February 17, 2015. On March 24, 2015, the Court issued an Order granting in part and denying in part the Motion to Dismiss. Specifically, the Court granted Omnicell's Motion to Dismiss with respect to Counts 4, 5, and 6 (declaratory judgments regarding PCT/US2007/003765, PCT/US2011/063597, and PCT/US2011/0635505) and count 13 (civil conspiracy). The Court denied the Company's Motion to Dismiss with respect to Count 9 (fraud), Count 7 (fraudulent concealment) and Count 8 (negligent misrepresentation). We Answered the Complaint on April 8, 2015. The Court held a Case Management Conference on April 22, 2015. At the Case Management Conference, the Court assigned this case to a “complex” track and ordered production of initial discovery regarding inventorship and sales of the relevant Omnicell products. No procedural schedule has been set. A status Conference with the court is scheduled for August 26, 2015. We intend to defend the matter vigorously. On March 19, 2015, a putative class action lawsuit was filed against the Company and two executive officers in the U.S. District Court for the Northern District of California, captioned Nelson v. Omnicell, Inc., et al., Case No. 3:15-cv-01280-HSG.The complaint purported to assert claims on behalf of a class of purchasers of the Company’s stock between May 2, 2014 and March 2, 2015. It alleged that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by purportedly making false and misleading statements regarding the existence of a “side letter” arrangement and the adequacy of internal controls that allegedly resulted in false and misleading financial statements. The Company believed that the claims had no merit and intended to defend the lawsuit vigorously. The Company and the individual defendants were not served with the complaint and on May 20, 2015, the plaintiff filed a notice of voluntary dismissal of the lawsuit without prejudice.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We provide for income taxes for each interim period based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 38.5% and 39.2% for the six months ended June 30, 2015 and June 30, 2014 , respectively. The 2015 and 2014 annual effective tax rate differed from the statutory rate of 35.0% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the domestic production activities deduction. We recorded a gain of $3.4 million attributable to the increase in the fair value of Omnicell's 15% minority interest in Avantec which was revalued in conjunction with our purchase of the remaining 85% of Avantec shares. This gain was treated as a discrete item and excluded from profit-before-tax in calculating the annual effective tax rate for the six months ended June 30, 2015 . The federal research and development credits law, which was extended through December 31, 2014, retroactively has not been extended to the end of 2015. As a result the annual effect tax rate for the six months ended June 30, 2015 and 2014 did not consider the effect of the federal research and development tax credit.

Stock Repurchases

Stock Repurchases	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stock Repurchases	Stock Repurchases In August 2012, our Board of Directors authorized a program (the "2012 Stock Repurchase Program") to repurchase up to $50.0 million of common stock, of which approximately $45.1 million had been repurchased as of December 31, 2014, and the remaining $4.9 million has been repurchased as of June 30, 2015 and the 2012 Stock Repurchase Program has concluded now. In November 2014, our Board of Directors authorized a program (the "2014 Stock Repurchase Program") to repurchase up to $50.0 million of common stock of which approximately $20.1 million had been repurchased as of June 30, 2015. The 2014 Stock Repurchase Program has a total of $29.9 million remaining for future repurchases as of June 30, 2015 , and the program has no expiration date. During the six months ended June 30, 2015 , we repurchased approximately 680 thousand shares under our stock repurchase programs. The following table summarizes our stock repurchases: June 30, December 31, (In thousands, except per share data) Total number of shares repurchased 680 884 Dollar amount of shares repurchased $ 25,020 $ 24,091 Average price paid per share $ 36.74 $ 27.24

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock Based plans For a detailed explanation of our stock plan and subsequent changes please refer to Note 16, Employee Benefits and Stock-Based Compensation, of our Annual Report on Form 10-K for the year ended December 31, 2014. Share-based compensation expense The following table sets forth the total share-based compensation expense recognized in our Condensed Consolidated Statements of Operations: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Cost of product and service revenues $ 532 $ 264 $ 1,049 $ 532 Research and development 451 380 885 749 Selling, general and administrative 2,653 2,076 5,367 4,168 Total share-based compensation expense $ 3,636 $ 2,720 $ 7,301 $ 5,449 The following weighted average assumptions are used to value share options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to our equity incentive plans for the three and six months ended June 30, 2015 and June 30, 2014: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Stock Option Plans Expected life, years 5.04 4.77 5.04 4.79 Expected volatility, % 29.3 % 35.9 % 32.2 % 35.4 % Risk free interest rate, % 1.51 % 1.62 % 1.58 % 1.52 % Estimated forfeiture rate % 2.5 % 2.5 % 2.5 % 2.5 % Dividend yield, % — % — % — % — % Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 28.52%-37.53% 29.56%-39.84% 23.75%-35.67% 29.56%-39.84% Risk free interest rate, % 0.03%-0.72% 0.03%-0.53% 0.03%-0.72% 0.03%-0.53% Estimated forfeiture rate % — % — % — % — % Dividend yield, % — % — % — % — % Stock option and restricted stock activity Stock options activity The following table summarizes the share option activity under the Company’s equity incentive plans during the six months ended June 30, 2015 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (1) (In thousands, except per share data) Stock Options Outstanding at December 31, 2014 2,672 $ 19.02 6.5 Granted 200 34.10 Exercised (340 ) 15.54 Expired (2 ) 15.57 Forfeited (67 ) 23.30 Outstanding at June 30, 2015 2,463 $ 20.60 6.5 $ 42,138 Exercisable at June 30, 2015 1,425 $ 16.46 4.9 $ 30,277 Vested and expected to vest at June 30, 2015 2,435 $ 20.50 6.4 $ 41,919 _________________________________________________ (1) Intrinsic value is calculated as the difference between the market value or closing price of our common stock as of the last trading day of the year as reported by the NASDAQ Global Select Market, and the exercise price of the option. The weighted-average fair value per share of options granted during the three and six months ended June 30, 2015 , was $10.09 and $10.61 , respectively and the weighted-average fair value per share of options granted during the three and six months ended June 30, 2014 was $9.00 and $8.29 , respectively. The intrinsic value of options exercised during the three and six months ended June 30, 2015 was $4.3 million and $6.7 million , respectively. The intrinsic value of options exercised during the three and six months ended June 30, 2014 was $5.3 million and $7.9 million , respectively. As of June 30, 2015 , total unrecognized compensation cost related to unvested stock options was $8.8 million , which is expected to be recognized over a weighted-average vesting period of 2.7 years. Restricted stock activity Restricted stock activity under the Company’s equity incentive plans in the six months ended June 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units (RSUs) Outstanding at December 31, 2014 399 $ 24.00 1.5 Granted 65 34.19 Vested (77 ) 21.57 Forfeited (23 ) 22.35 Outstanding and unvested at June 30, 2015 364 $ 26.45 1.3 $ 13,714 Expected to vest at June 30, 2015 353 1.3 $ 13,329 The weighted-average grant date fair value per share of RSUs granted during the six months ended June 30, 2015 was $34.19 , respectively. The weighted-average grant date fair value per share of RSUs granted during the six months ended June 30, 2014 was $26.46 , respectively. As of June 30, 2015 , total unrecognized compensation expense related to RSUs was $8.4 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.4 years . Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards (RSAs) Outstanding at December 31, 2014 36 $ 26.47 Granted 37 36.05 Vested (41 ) 26.47 Forfeited (1 ) 27.65 Outstanding and unvested at June 30, 2015 31 $ 35.95 The weighted-average grant date fair value per share of RSAs granted during the six months ended June 30, 2015 was and $36.05 . As of June 30, 2015 , total unrecognized compensation cost related to RSAs was $1.0 million , which is expected to be recognized over the remaining weighted-average vesting period of 0.9 years . Performance-based restricted stock units activity Performance-based restricted stock activity under the Company’s equity incentive plans in the six months ended June 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units (PSUs) Outstanding at December 31, 2014 233 $ 17.96 Granted 60 29.56 Vested (70 ) 18.91 Forfeited (27 ) 14.69 Outstanding and unvested at June 30, 2015 196 $ 21.63 The weighted-average grant date fair value per share of PSUs granted during the six months ended June 30, 2015 and June 30, 2014 was $29.56 and $16.49 , respectively. The total fair value of PSUs that vested during the six months ended June 30, 2015 and June 30, 2014 was $2.6 million and $2.1 million , respectively. As of June 30, 2015 , total unrecognized compensation cost related to PSUs was approximately $2.5 million , which is expected to be recognized over the remaining weighted-average period of 1.4 years . Employee Stock Purchase Plan (ESPP) activity The unrecognized compensation cost related to the shares to be purchased under our ESPP was approximately $2.2 million as of June 30, 2015 , and is expected to be recognized over a weighted-average period of 0.1 years . Summary of shares reserved for future issuance under equity incentive plans We had the following ordinary shares reserved for future issuance under its equity incentive plans as of June 30, 2015: Number of Shares (In thousands) Share options outstanding 2,463 Restricted share awards outstanding 559 Shares authorized for future issuance 4,637 ESPP shares available for future issuance 3,393 Total shares reserved for future issuance as of June 30, 2015 11,052

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Information	Segment Information In the first quarter of 2015, we modified the segment presentation to reflect the changes in how our Chief Operating Decision Maker (“CODM”) reviews the segments and the overall business. With the increase in completed acquisitions in the last two years , we changed how the financial information was presented for CODM review to exclude general corporate-level costs that are not specific to either of the reporting segments when evaluating the operating results of each segment. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The historical information presented has been retrospectively adjusted to reflect the modified segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations, excluding certain costs which are managed separately at the corporate level. We enhanced our segment reporting structure to match our operating structure based on how our Chief Operating Decision Maker (“CODM”) views the business and allocates resources, beginning in the first quarter of 2015. Our CODM is our Chief Executive Officer. Retrospective adjustments of prior period financial information have been made to conform to the current period presentation. The two operating segments, which are the same as our reportable segments, are as follows: Automation and Analytics The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. Our Automation and Analytics products are designed to enable our customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, our systems can be tailored to specific customer needs. Medication Adherence The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. These products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS Medication Technologies ("MTS"), Surgichem Limited ("Surgichem"), and under the Omnicell and Suremed brands. MTS products consist of proprietary medication packaging systems and related products for use by institutional pharmacies servicing long-term care, and correctional facilities or retail pharmacies serving patients in their local communities. The following table summarizes the financial performance of our reportable segments, including a reconciliation of income from segment operations to income from total operations: Three Months Ended June 30, 2015 June 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 88,701 $ 24,087 $ 112,788 $ 84,702 $ 20,350 $ 105,052 Cost of revenues 39,403 15,923 55,326 35,992 13,020 49,012 Gross profit 49,298 8,164 57,462 48,710 7,330 56,040 Operating expenses 25,978 5,910 31,888 26,044 4,800 30,844 Income from segment operations $ 23,320 $ 2,254 $ 25,574 $ 22,666 $ 2,530 $ 25,196 Corporate costs 13,150 12,638 Income from operations $ 12,424 $ 12,558 Six Months Ended June 30, 2015 June 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 181,480 $ 47,529 $ 229,009 $ 166,201 $ 40,615 $ 206,816 Cost of revenues 78,255 31,607 109,862 70,932 25,349 96,281 Gross profit 103,225 15,922 119,147 95,269 15,266 110,535 Operating expenses 54,567 12,251 66,818 51,146 9,451 60,597 Income from segment operations $ 48,658 $ 3,671 $ 52,329 $ 44,123 $ 5,815 $ 49,938 Corporate costs 29,526 27,426 Income from operations $ 22,803 $ 22,512 _________________________________________________ Significant customers There were no customers that accounted for more than 10% of our total revenues for the three and six months ended June 30, 2015 and three and six months ended June 30, 2014 .

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of June 30, 2015 and December 31, 2014 , the results of their operations, comprehensive income and cash flows for the three and six months ended June 30, 2015 and June 30, 2014 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in our annual report on Form 10-K for the year ended December 31, 2014 . Our results of operations, comprehensive income and cash flows for the three and six months ended June 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015 , or for any future period.
Principles of consolidation	Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On April 21, 2015, we completed the acquisition of Mach4 Automatisierungstechnik GmbH (“Mach4”), a privately held German limited liability company with registered office in Bochum, Germany. On April 30, 2015, we acquired the 85% of the issued and outstanding ordinary shares of Avantec Healthcare Limited (“Avantec”) not already held by Omnicell. Omnicell previously had a 15% interest in Avantec. The consolidated financial statements include the results of operations of Mach4 and Avantec commencing as of their respective acquisition dates.
Use of estimates	Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, accounts receivable and notes receivable (net investment in sales-type leases), valuation of goodwill, purchased intangibles and long-lived assets, and accounting for income taxes.
Segment reporting change	Segment reporting change As previously disclosed, since the first quarter of 2015, we modified the segment presentation to reflect the changes in how our Chief Operating Decision Maker (“CODM”) reviews the segments and the overall business. This change does not impact previously reported Condensed Consolidated Financial Statements. See Note 14, Segment Information, for additional information on our segment reporting change. Our CODM is our Chief Executive Officer. With the increase in completed acquisitions in the last two years , our CODM changed how the financial information was reviewed to exclude general corporate-level costs that are not specific to either of the reporting segments when evaluating the operating results of each segment. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The historical information presented has been retrospectively adjusted to reflect the modified segment reporting. Our CODM allocates resources and evaluates the performance of our segments using information about its revenues, gross profit and income from operations, excluding certain costs which are managed separately at the corporate level. We enhanced our segment reporting structure to match our operating structure based on how our CODM views the business and allocates resources, beginning in the first quarter of 2015.
Concentration of credit risk	Concentration of credit risk Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there were no customers that accounted for more than 10% of our accounts receivable as of June 30, 2015 and December 31, 2014 . We believe that we have no significant concentrations of credit risk as of June 30, 2015 .
Recently issued authoritative guidance	Recently issued authoritative guidance In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which provides new guidance on the recognition of revenue and states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard will be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted, however, in July 2015, the FASB voted to approve deferring the effective date by one year (i.e., interim and annual reporting periods beginning after December 15, 2017). Early adoption is permitted, but not before the original effective date (i.e., interim and annual reporting periods beginning after December 15, 2016). For financial reporting purposes, the standard allows for either full retrospective adoption, meaning the standard is applied to all of the periods presented, or modified retrospective adoption, meaning the standard is applied only to the most current period presented in the financial statements with the cumulative effect of initially applying the standard recognized at the date of initial application. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial position or results of operations. There was no other recently issued authoritative guidance that has a material impact on our Condensed Consolidated Financial Statements through the reporting date.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The calculation of basic and diluted net income per share is as follows: Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 (In thousands, except per share data) Net income $ 8,751 $ 7,789 $ 15,069 $ 13,983 Weighted-average shares outstanding — basic 36,120 35,661 36,072 35,451 Dilutive effect of employee stock plans 910 957 915 1,027 Weighted-average shares outstanding — diluted 37,030 36,618 36,987 36,478 Net income per share — basic $ 0.24 $ 0.22 $ 0.42 $ 0.39 Net income per share — diluted $ 0.24 $ 0.21 $ 0.41 $ 0.38 Anti-dilutive weighted-average shares related to stock award plans 377 353 356 1,347

Cash and Cash Equivalents and23

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value On A Recurring Basis	The following table summarizes our assets measured at fair value on a recurring basis using Level 1 inputs within the fair value hierarchy: June 30, December 31, (In thousands) Cash $ 27,925 $ 61,311 Money market fund 60,103 64,577 Total cash and cash equivalents $ 88,028 $ 125,888
Schedule of Financial Assets Measured At Fair Value	The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of June 30, 2015 : Level 1 Level 2 Total (In thousands) Money market funds $ 60,103 $ — $ 60,103 Total financial assets $ 60,103 $ — $ 60,103 Derivative contracts $ — $ 92 $ 92 Total financial liabilities $ — $ 92 $ 92 The following table represents the fair value hierarchy of the Company’s financial asset measured at fair value as of December 31, 2014 : Level 1 Level 2 Total (In thousands) Money market fund $ 64,577 $ — $ 64,577 Total financial assets $ 64,577 $ — $ 64,577

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Balance Sheet	June 30, December 31, (In thousands) Inventories: Raw materials $ 10,725 $ 8,254 Work in process 2,554 64 Finished goods 32,748 23,236 Total inventories, net $ 46,027 $ 31,554 Property and Equipment: Equipment $ 43,717 $ 42,829 Furniture and fixtures 5,895 5,689 Leasehold improvements 8,991 8,701 Purchased software 29,729 28,920 Construction in progress 3,982 1,538 92,314 87,677 Accumulated depreciation and amortization (57,542 ) (51,499 ) Total Property and equipment, net $ 34,772 $ 36,178 Other long term assets: Capitalized software, net $ 23,066 $ 19,643 Other assets 2,316 3,630 Total Other long term assets, net $ 25,382 $ 23,273 Accrued liabilities: Rebates and lease buyouts $ 7,253 $ 6,512 Advance payments from customers 7,840 4,834 Group purchasing organization fees 3,007 3,475 Taxes payable 3,488 2,181 Other Accrued liabilities 11,831 2,297 Total Accrued liabilities $ 33,419 $ 19,299

Net Investment in Sales-Type 25

Net Investment in Sales-Type Leases (Tables)	6 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	Net investment in sales-type leases consists of the following components: June 30, December 31, (In thousands) Net minimum lease payments to be received $ 16,674 $ 17,616 Less: unearned interest income portion (1,118 ) (1,131 ) Net investment in sales-type leases 15,556 16,485 Less: short-term portion (5,348 ) (5,637 ) Long-term net investment in sales-type leases $ 10,208 $ 10,848
Schedule of Net Sale-Type Leases Minimum Lease Receivables	The minimum lease payments under sales-type leases are as follows: June 30, (In thousands) Remainder of 2015 $ 3,147 2016 5,308 2017 4,281 2018 2,652 2019 1,054 Thereafter 232 Total $ 16,674

Business Acquisitions (Tables)

Business Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed and Weighted Average Useful Life	Our preliminary allocation of the total purchase price for each transaction is summarized below: Mach4 Avantec Total (In thousands) Cash $ 397 $ 3,392 $ 3,789 Accounts receivable 3,743 3,607 7,350 Inventory 3,580 1,428 5,008 Deferred tax assets and other current assets 368 89 457 Total current assets 8,088 8,516 16,604 Property and equipment 463 — 463 Intangibles 7,710 6,341 14,051 Goodwill 10,520 15,606 26,126 Other non-current assets 52 — 52 Total assets 26,833 30,463 57,296 Current liabilities 3,684 4,125 7,809 Non-current deferred tax liabilities 2,564 1,269 3,833 Deferred service revenue and gross profit 2,314 928 3,242 Other non-current liabilities 1,056 — 1,056 Total purchase price $ 17,215 $ 24,141 $ 41,356 Total purchase price, net of cash received $ 16,818 $ 20,749 $ 37,567 Intangible assets acquired and their respective estimated remaining useful lives over which each asset will be amortized are as follows: Mach4 Avantec Fair Value Weighted Fair Value Weighted Average Useful life (In thousands) (In years) (In thousands) (In years) Developed Technology $ 3,290 8 $ — — Trade name 850 6 92 2 Customer relationships 3,570 11-12 5,834 12 Backlog — — 415 2 Total purchased intangible assets $ 7,710 $ 6,341
Pro Forma Information	As a result, actual results will differ from the unaudited pro forma information presented (in thousands, except per share data): Six Months Ended June 30, 2015 2014 (In thousands, except per share data) Pro forma net revenues $ 236,000 $ 220,000 Pro forma net income $ 15,700 $ 14,400 Pro forma net income per share basic $ 0.44 $ 0.41 Pro forma net income per share diluted $ 0.42 $ 0.39

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2014 $ 28,543 $ 94,177 $ 122,720 Goodwill acquired - Mach4 10,520 — 10,520 Goodwill acquired - Avantec 15,606 — 15,606 Foreign currency exchange rate fluctuations 729 79 808 Net balance as of June 30, 2015 $ 55,398 $ 94,256 $ 149,654
Intangible Assets, Net	The carrying amounts of intangibles as of June 30, 2015 are as follows: June 30, 2015 Gross Carrying Amount Accumulated Amortization Foreign Currency Exchange Rate Fluctuations Net Carrying Amount Useful Life (Years) (In thousands, except for years) Customer relationships $ 69,554 $ (9,182 ) $ (94 ) $ 60,278 5 - 30 Acquired technology 30,870 (4,967 ) 122 26,025 3 - 20 Trade names 8,052 (2,012 ) 2 6,042 1 - 12 Patents 1,879 (320 ) — 1,559 2 - 20 Backlog 415 (42 ) 8 381 1.7 Total intangibles assets, net $ 110,770 $ (16,523 ) $ 38 $ 94,285 The carrying amounts of intangibles as of December 31, 2014 are as follows: December 31, 2014 Gross Carrying Amount Accumulated Amortization Foreign currency exchange rate fluctuations Net Carrying Amount Useful Life (Years) Customer relationships $ 60,150 $ (7,596 ) $ (323 ) $ 52,231 5 - 30 Acquired technology 27,580 (4,068 ) — 23,512 3 - 20 Trade names 7,110 (1,559 ) (17 ) 5,534 3 - 12 Patents 1,655 (265 ) — 1,390 2 - 20 Total intangibles assets, net $ 96,495 $ (13,488 ) $ (340 ) $ 82,667
Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for intangible assets are as follows: June 30, (In thousands) Remainder of 2015 $ 3,510 2016 6,599 2017 5,843 2018 5,463 2019 5,297 Thereafter 67,573 Total $ 94,285

Deferred Gross Profit (Tables)

Deferred Gross Profit (Tables)	6 Months Ended
	Jun. 30, 2015
Revenue Recognition [Abstract]
Schedule of Deferred Gross Profit	Deferred gross profit consists of the following: June 30, December 31, (In thousands) Sales of medication and supply dispensing systems including packaging equipment (1) $ 55,304 $ 36,947 Less: cost of revenues, excluding installation costs (18,633 ) (8,389 ) Total deferred gross profit $ 36,671 $ 28,558 _________________________________________________ (1) Delivered and invoiced, pending installation.

Commitments (Tables)

Commitments (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Payments on Non-Cancelable Operating Leases	The minimum future payments on non-cancelable operating leases are as follows: June 30, (In thousands) Remainder of 2015 $ 3,421 2016 6,557 2017 5,900 2018 5,487 2019 5,490 Thereafter 15,295 Total minimum future lease payments $ 42,150

Stock Repurchases (Tables)

Stock Repurchases (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Stock Repurchases	The following table summarizes our stock repurchases: June 30, December 31, (In thousands, except per share data) Total number of shares repurchased 680 884 Dollar amount of shares repurchased $ 25,020 $ 24,091 Average price paid per share $ 36.74 $ 27.24

Employee Benefits and Share-B31

Employee Benefits and Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in our Condensed Consolidated Statements of Operations: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Cost of product and service revenues $ 532 $ 264 $ 1,049 $ 532 Research and development 451 380 885 749 Selling, general and administrative 2,653 2,076 5,367 4,168 Total share-based compensation expense $ 3,636 $ 2,720 $ 7,301 $ 5,449
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	The following weighted average assumptions are used to value share options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to our equity incentive plans for the three and six months ended June 30, 2015 and June 30, 2014: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Stock Option Plans Expected life, years 5.04 4.77 5.04 4.79 Expected volatility, % 29.3 % 35.9 % 32.2 % 35.4 % Risk free interest rate, % 1.51 % 1.62 % 1.58 % 1.52 % Estimated forfeiture rate % 2.5 % 2.5 % 2.5 % 2.5 % Dividend yield, % — % — % — % — % Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 28.52%-37.53% 29.56%-39.84% 23.75%-35.67% 29.56%-39.84% Risk free interest rate, % 0.03%-0.72% 0.03%-0.53% 0.03%-0.72% 0.03%-0.53% Estimated forfeiture rate % — % — % — % — % Dividend yield, % — % — % — % — %
Estimate of Fair Value of Share-Based Awards, Stock Options	The following weighted average assumptions are used to value share options and Employee Stock Purchase Plan ("ESPP") shares issued pursuant to our equity incentive plans for the three and six months ended June 30, 2015 and June 30, 2014: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Stock Option Plans Expected life, years 5.04 4.77 5.04 4.79 Expected volatility, % 29.3 % 35.9 % 32.2 % 35.4 % Risk free interest rate, % 1.51 % 1.62 % 1.58 % 1.52 % Estimated forfeiture rate % 2.5 % 2.5 % 2.5 % 2.5 % Dividend yield, % — % — % — % — % Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (In thousands) Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 0.5-2.0 0.5-2.0 Expected volatility, % 28.52%-37.53% 29.56%-39.84% 23.75%-35.67% 29.56%-39.84% Risk free interest rate, % 0.03%-0.72% 0.03%-0.53% 0.03%-0.72% 0.03%-0.53% Estimated forfeiture rate % — % — % — % — % Dividend yield, % — % — % — % — %
Stock Option Activity under the 2009 Plan	The following table summarizes the share option activity under the Company’s equity incentive plans during the six months ended June 30, 2015 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (1) (In thousands, except per share data) Stock Options Outstanding at December 31, 2014 2,672 $ 19.02 6.5 Granted 200 34.10 Exercised (340 ) 15.54 Expired (2 ) 15.57 Forfeited (67 ) 23.30 Outstanding at June 30, 2015 2,463 $ 20.60 6.5 $ 42,138 Exercisable at June 30, 2015 1,425 $ 16.46 4.9 $ 30,277 Vested and expected to vest at June 30, 2015 2,435 $ 20.50 6.4 $ 41,919 _________________________________________________ (1) Intrinsic value is calculated as the difference between the market value or closing price of our common stock as of the last trading day of the year as reported by the NASDAQ Global Select Market, and the exercise price of the option.
Restricted Stock Units Activity under the 2009 Plan	Restricted stock activity under the Company’s equity incentive plans in the six months ended June 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units (RSUs) Outstanding at December 31, 2014 399 $ 24.00 1.5 Granted 65 34.19 Vested (77 ) 21.57 Forfeited (23 ) 22.35 Outstanding and unvested at June 30, 2015 364 $ 26.45 1.3 $ 13,714 Expected to vest at June 30, 2015 353 1.3 $ 13,329
Restricted Stock Units Award under the 2009 Plan	Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards (RSAs) Outstanding at December 31, 2014 36 $ 26.47 Granted 37 36.05 Vested (41 ) 26.47 Forfeited (1 ) 27.65 Outstanding and unvested at June 30, 2015 31 $ 35.95
Performance Shares Restricted Stock Activity under the 2009 Plan	Performance-based restricted stock activity under the Company’s equity incentive plans in the six months ended June 30, 2015 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units (PSUs) Outstanding at December 31, 2014 233 $ 17.96 Granted 60 29.56 Vested (70 ) 18.91 Forfeited (27 ) 14.69 Outstanding and unvested at June 30, 2015 196 $ 21.63
Shares Reserved for Future Issuance	We had the following ordinary shares reserved for future issuance under its equity incentive plans as of June 30, 2015: Number of Shares (In thousands) Share options outstanding 2,463 Restricted share awards outstanding 559 Shares authorized for future issuance 4,637 ESPP shares available for future issuance 3,393 Total shares reserved for future issuance as of June 30, 2015 11,052

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following table summarizes the financial performance of our reportable segments, including a reconciliation of income from segment operations to income from total operations: Three Months Ended June 30, 2015 June 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 88,701 $ 24,087 $ 112,788 $ 84,702 $ 20,350 $ 105,052 Cost of revenues 39,403 15,923 55,326 35,992 13,020 49,012 Gross profit 49,298 8,164 57,462 48,710 7,330 56,040 Operating expenses 25,978 5,910 31,888 26,044 4,800 30,844 Income from segment operations $ 23,320 $ 2,254 $ 25,574 $ 22,666 $ 2,530 $ 25,196 Corporate costs 13,150 12,638 Income from operations $ 12,424 $ 12,558 Six Months Ended June 30, 2015 June 30, 2014 Automation and Analytics Medication Adherence Total Automation and Analytics Medication Adherence Total (In thousands) Revenues $ 181,480 $ 47,529 $ 229,009 $ 166,201 $ 40,615 $ 206,816 Cost of revenues 78,255 31,607 109,862 70,932 25,349 96,281 Gross profit 103,225 15,922 119,147 95,269 15,266 110,535 Operating expenses 54,567 12,251 66,818 51,146 9,451 60,597 Income from segment operations $ 48,658 $ 3,671 $ 52,329 $ 44,123 $ 5,815 $ 49,938 Corporate costs 29,526 27,426 Income from operations $ 22,803 $ 22,512 _________________________________________________

Organization and Summary of S33

Organization and Summary of Significant Accounting Policies - (Details)	6 Months Ended
	Jun. 30, 2015	Apr. 30, 2015	Apr. 29, 2014
Business Acquisition [Line Items]
Period of completed acquisitions	2 years
Avantec [Member]
Business Acquisition [Line Items]
Percentage of interest acquired		85.00%
Avantec [Member]
Business Acquisition [Line Items]
Percentage of ownership under the equity method			15.00%

Net Income Per Share - (Basic a

Net Income Per Share - (Basic and Diluted Net Income Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Net income	$ 8,751	$ 7,789	$ 15,069	$ 13,983
Weighted-average shares outstanding — basic	36,120	35,661	36,072	35,451
Dilutive effect of employee stock plans (in shares)	910	957	915	1,027
Weighted-average shares outstanding — diluted	37,030	36,618	36,987	36,478
Net income per share — basic	$ 0.24	$ 0.22	$ 0.42	$ 0.39
Net income per share — diluted	$ 0.24	$ 0.21	$ 0.41	$ 0.38
Anti-dilutive weighted-average shares related to stock award plans (in shares)	377	353	356	1,347

Cash and Cash Equivalents and35

Cash and Cash Equivalents and Fair Value of Financial Instruments - Assets Measured at Fair Value On A Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 60,103	$ 64,577
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	60,103	64,577
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	27,925	61,311
Money market funds	60,103	64,577
Total cash and cash equivalents	$ 88,028	$ 125,888

Cash and Cash Equivalents and36

Cash and Cash Equivalents and Fair Value of Financial Instruments - Schedule of Financial Assets Measured At Fair Value (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 60,103,000	$ 64,577,000
Total financial assets	60,103,000	64,577,000
Total financial liabilities	92,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	60,103,000	64,577,000
Total financial assets	60,103,000	64,577,000
Total financial liabilities	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	0	0
Total financial assets	0	0
Total financial liabilities	92,000
Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative contracts	92,000
Foreign Exchange Forward [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative contracts	0
Foreign Exchange Forward [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative contracts	$ 92,000	$ 0

Cash and Cash Equivalents and37

Cash and Cash Equivalents and Fair Value of Financial Instruments - Foreign Currency Risk Management (Details) - Foreign Exchange Forward [Member] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Derivative, notional amount	$ 2,200,000
Aggregate fair value of outstanding derivative	92,000
Fair Value, Inputs, Level 2 [Member]
Derivatives, Fair Value [Line Items]
Aggregate fair value of outstanding derivative	$ 92,000	$ 0

Balance Sheet Components (Detai

Balance Sheet Components (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventories:
Raw materials	$ 10,725	$ 8,254
Work in process	2,554	64
Finished goods	32,748	23,236
Total inventories, net	46,027	31,554
Property and Equipment:
Equipment	43,717	42,829
Furniture and fixtures	5,895	5,689
Leasehold improvements	8,991	8,701
Purchased software	29,729	28,920
Construction in progress	3,982	1,538
Property and equipment, gross	92,314	87,677
Accumulated depreciation and amortization	(57,542)	(51,499)
Total Property and equipment, net	34,772	36,178
Other long term assets:
Capitalized software, net	23,066	19,643
Other assets	2,316	3,630
Total Other long term assets, net	25,382	23,273
Accrued liabilities:
Rebates and lease buyouts	7,253	6,512
Advance payments from customers	7,840	4,834
Group purchasing organization fees	3,007	3,475
Taxes payable	3,488	2,181
Other Accrued liabilities	11,831	2,297
Total Accrued liabilities	$ 33,419	$ 19,299

Net Investment in Sales-Type 39

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Leases [Abstract]
Terms of sales-type leases (generally up to five years in length)	5 years
Net minimum lease payments to be received	$ 16,674,000	$ 17,616,000
Less: unearned interest income portion	(1,118,000)	(1,131,000)
Net investment in sales-type leases	15,556,000	16,485,000
Less: short-term portion	(5,348,000)	(5,637,000)
Long-term net investment in sales-type leases	10,208,000	10,848,000
Collective allowance for credit losses	$ 0	$ 200,000

Net Investment in Sales-Type 40

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) $ in Thousands	Jun. 30, 2015USD ($)
Leases [Abstract]
Remainder of 2015	$ 3,147
2,016	5,308
2,017	4,281
2,018	2,652
2,019	1,054
Thereafter	232
Total	$ 16,674

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Details) - USD ($) $ in Thousands	Apr. 30, 2015	Apr. 21, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Apr. 29, 2014
Business Acquisition [Line Items]
Difference between fair value and carrying value as a gain			$ 3,443	$ 0	$ 3,443	$ 0
Avantec [Member]
Business Acquisition [Line Items]
Percentage of ownership under the equity method							15.00%
Business acquisition, amount withheld for idemnification	$ 1,800
Carrying book value of previous equity interest	$ 1,300
Fair value of equity investment			4,700
Difference between fair value and carrying value as a gain			3,400
Mach4 [Member]
Business Acquisition [Line Items]
Payment to acquire business, amount in cash after adjustments		$ 17,200
Amount placed in escrow fund for business acquisition		$ 2,700
Period after closing date to settle indemnification and other claims		18 months
Mach4 [Member] | Developed Technology [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Discount rate		17.50%
Royalty rate		5.00%
Mach4 [Member] | Trade names [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Royalty rate		2.00%
Mach4 [Member] | Minimum [Member] | Developed Technology [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Discount rate		1.50%
Avantec [Member]
Business Acquisition [Line Items]
Period after closing date to settle indemnification and other claims	18 months
Percentage of interest acquired	85.00%
Payment to acquire business, in cash	$ 12,000
Business acquisition, potential earn-out payment	$ 5,600
Difference between fair value and carrying value as a gain			$ 3,400
Avantec [Member] | Trade names [Member] | Income Approach Valuation Technique [Member]
Business Acquisition [Line Items]
Royalty rate	1.00%
Avantec [Member] | Payable After December 31, 2015 [Member]
Business Acquisition [Line Items]
Business acquisition, potential earn-out payment	$ 3,000
Avantec [Member] | Payable After December 31, 2016 [Member]
Business Acquisition [Line Items]
Business acquisition, potential earn-out payment	$ 3,000

Business Acquisitions - Total P

Business Acquisitions - Total Purchase Price and Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Apr. 30, 2015	Apr. 30, 2015	Apr. 21, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Total Purchase Price
Cash	$ 3,789	$ 3,789
Accounts receivable	7,350	7,350
Inventory	5,008	5,008
Deferred tax assets and other current assets	457	457
Total current assets	16,604	16,604
Property and equipment	463	463
Intangibles	14,051	14,051
Goodwill	26,126	26,126		$ 149,654		$ 122,720
Other non-current assets	52	52
Total assets	57,296	57,296
Current liabilities	7,809	7,809
Non-current deferred tax liabilities	3,833	3,833
Deferred service revenue and gross profit	3,242	3,242
Other non-current liabilities	1,056	1,056
Total purchase price	41,356	41,356
Total purchase price, net of cash received		37,567		$ 23,625	$ 0
Mach4 [Member]
Total Purchase Price
Cash			$ 397
Accounts receivable			3,743
Inventory			3,580
Deferred tax assets and other current assets			368
Total current assets			8,088
Property and equipment			463
Intangibles			7,710
Goodwill			10,520
Other non-current assets			52
Total assets			26,833
Current liabilities			3,684
Non-current deferred tax liabilities			2,564
Deferred service revenue and gross profit			2,314
Other non-current liabilities			1,056
Total purchase price			17,215
Total purchase price, net of cash received			16,818
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			7,710
Avantec [Member]
Total Purchase Price
Cash	3,392	3,392
Accounts receivable	3,607	3,607
Inventory	1,428	1,428
Deferred tax assets and other current assets	89	89
Total current assets	8,516	8,516
Property and equipment	0	0
Intangibles	6,341	6,341
Goodwill	15,606	15,606
Other non-current assets	0	0
Total assets	30,463	30,463
Current liabilities	4,125	4,125
Non-current deferred tax liabilities	1,269	1,269
Deferred service revenue and gross profit	928	928
Other non-current liabilities	0	0
Total purchase price	24,141	$ 24,141
Total purchase price, net of cash received	20,749
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	6,341
Developed Technology [Member] | Mach4 [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			$ 3,290
Weighted average useful life (in years)			8 years
Trade names [Member] | Mach4 [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			$ 850
Weighted average useful life (in years)			6 years
Trade names [Member] | Avantec [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	$ 92
Weighted average useful life (in years)	2 years
Customer relationships [Member] | Mach4 [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased			$ 3,570
Customer relationships [Member] | Avantec [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	$ 5,834
Weighted average useful life (in years)	12 years
Backlog [Member] | Avantec [Member]
Identifiable Intangible Assets
Fair value of identifiable intangible assets purchased	$ 415
Weighted average useful life (in years)	2 years
Minimum [Member] | Customer relationships [Member] | Mach4 [Member]
Identifiable Intangible Assets
Weighted average useful life (in years)			11 years
Maximum [Member] | Customer relationships [Member] | Mach4 [Member]
Identifiable Intangible Assets
Weighted average useful life (in years)			12 years

Business Acquisitions - Pro For

Business Acquisitions - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Business Combinations [Abstract]
Pro forma net revenues	$ 236,000	$ 220,000
Pro forma net income	$ 15,700	$ 14,400
Pro forma net income (loss) per share basic (in dollars per share)	$ 0.44	$ 0.41
Pro forma net income (loss) per share diluted (in dollars per share)	$ 0.42	$ 0.39

Goodwill and Intangible Asset44

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Goodwill [Roll Forward]
Net balance as of December 31, 2014	$ 122,720
Foreign currency exchange rate fluctuations	808
Net balance as of June 30, 2015	149,654
Automation and Analytics [Member]
Goodwill [Roll Forward]
Net balance as of December 31, 2014	28,543
Foreign currency exchange rate fluctuations	729
Net balance as of June 30, 2015	55,398
Medication Adherence [Member]
Goodwill [Roll Forward]
Net balance as of December 31, 2014	94,177
Foreign currency exchange rate fluctuations	79
Net balance as of June 30, 2015	94,256
Mach4 [Member]
Goodwill [Roll Forward]
Goodwill acquired - Mach4	10,520
Mach4 [Member] | Automation and Analytics [Member]
Goodwill [Roll Forward]
Goodwill acquired - Mach4	10,520
Mach4 [Member] | Medication Adherence [Member]
Goodwill [Roll Forward]
Goodwill acquired - Mach4	0
Avantec [Member]
Goodwill [Roll Forward]
Goodwill acquired - Mach4	15,606
Avantec [Member] | Automation and Analytics [Member]
Goodwill [Roll Forward]
Goodwill acquired - Mach4	15,606
Avantec [Member] | Medication Adherence [Member]
Goodwill [Roll Forward]
Goodwill acquired - Mach4	$ 0

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	$ 110,770	$ 96,495
Intangible Assets, Accumulated Amortization	(16,523)	(13,488)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	38	(340)
Total Intangibles Assets, Net Carrying Amount	94,285	82,667
Customer relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	69,554	60,150
Intangible Assets, Accumulated Amortization	(9,182)	(7,596)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	(94)	(323)
Total Intangibles Assets, Net Carrying Amount	60,278	52,231
Acquired technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	30,870	27,580
Intangible Assets, Accumulated Amortization	(4,967)	(4,068)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	122	0
Total Intangibles Assets, Net Carrying Amount	26,025	23,512
Trade names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	8,052	7,110
Intangible Assets, Accumulated Amortization	(2,012)	(1,559)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	2	(17)
Total Intangibles Assets, Net Carrying Amount	6,042	5,534
Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	1,879	1,655
Intangible Assets, Accumulated Amortization	(320)	(265)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	0	0
Total Intangibles Assets, Net Carrying Amount	1,559	$ 1,390
Backlog [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross Carrying Amount	415
Intangible Assets, Accumulated Amortization	(42)
Intangible Assets, Foreign Currency Exchange Rate Fluctuations	8
Total Intangibles Assets, Net Carrying Amount	$ 381
Useful Life	1 year 8 months 12 days
Maximum [Member] | Customer relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	30 years	30 years
Maximum [Member] | Acquired technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years	20 years
Maximum [Member] | Trade names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years
Maximum [Member] | Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	20 years	20 years
Minimum [Member] | Customer relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years	5 years
Minimum [Member] | Acquired technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Minimum [Member] | Trade names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year	3 years
Minimum [Member] | Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful Life	2 years	2 years

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1.8	$ 1.1	$ 3.1	$ 2.2

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2015	$ 3,510
2,016	6,599
2,017	5,843
2,018	5,463
2,019	5,297
Thereafter	67,573
Total Intangibles Assets, Net Carrying Amount	$ 94,285	$ 82,667

Deferred Gross Profit - Additio

Deferred Gross Profit - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total deferred gross profit	$ 36,671	$ 28,558
Products with Installation Services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales of medication and supply dispensing systems including packaging equipment	55,304	36,947
Less: cost of revenues, excluding installation costs	(18,633)	(8,389)
Total deferred gross profit	$ 36,671	$ 28,558

Commitments - Minimum Future Pa

Commitments - Minimum Future Payments on Non-Cancelable Operating Leases (Details) $ in Thousands	Jun. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2015	$ 3,421
2,016	6,557
2,017	5,900
2,018	5,487
2,019	5,490
Thereafter	15,295
Total minimum future lease payments	42,150
Technology license purchase obligation	$ 25,200

Contingencies - Additional Info

Contingencies - Additional Information (Details)	Mar. 19, 2015Executive_Officer
Commitments and Contingencies Disclosure [Abstract]
Number of executive officers in the Nelson v. Omnicell putative class action lawsuit	2

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Apr. 30, 2015	Apr. 29, 2014
Income Tax Disclosure [Abstract]
Effective tax rate			38.50%	39.20%
Statutory income tax rate			35.00%		35.00%
Gain on business combination	$ 3,443	$ 0	$ 3,443	$ 0
Avantec [Member]
Income Tax Disclosure [Abstract]
Gain on business combination	3,400
Business Acquisition [Line Items]
Percentage of minority interest							15.00%
Avantec [Member]
Income Tax Disclosure [Abstract]
Gain on business combination	$ 3,400
Business Acquisition [Line Items]
Percentage of interest acquired						85.00%

Stock Repurchases - Additional

Stock Repurchases - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands	6 Months Ended	8 Months Ended	12 Months Ended	29 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2014	Nov. 30, 2014	Aug. 31, 2012
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, remaining authorized repurchase amount	$ 29,900,000	$ 29,900,000
Total number of shares repurchased	680		884
Dollar amount of shares repurchased	$ 25,020,000		$ 24,091,000
Average price paid per share	$ 36.74		$ 27.24
August 2012 Stock Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount						$ 50,000,000
Stock repurchases program, amount repurchased	$ 4,900,000			$ 45,100,000
November 2014 Stock Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchases program, authorized amount					$ 50,000,000
Stock repurchases program, amount repurchased		$ 20,100,000

Employee Benefits and Share-B53

Employee Benefits and Share-Based Compensation - Shared-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 3,636	$ 2,720	$ 7,301	$ 5,449
Cost of product and service revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	532	264	1,049	532
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	451	380	885	749
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 2,653	$ 2,076	$ 5,367	$ 4,168

Employee Benefits and Share-B54

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards, Table (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life, years	5 years 15 days	4 years 9 months 7 days	5 years 15 days	4 years 9 months 15 days
Expected volatility, %	29.30%	35.90%	32.20%	35.40%
Risk free interest rate, %	1.51%	1.62%	1.58%	1.52%
Estimated forfeiture rate %	2.50%	2.50%	2.50%	2.50%
Dividend yield, %	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, %, Min	28.52%	29.56%	23.75%	29.56%
Expected volatility, %, Max	37.53%	39.84%	35.67%	39.84%
Risk free interest rate, %, Min	0.03%	0.03%	0.03%	0.03%
Risk free interest rate, %, Max	0.72%	0.53%	0.72%	0.53%
Estimated forfeiture rate %	0.00%	0.00%	0.00%	0.00%
Dividend yield, %	0.00%	0.00%	0.00%	0.00%
Minimum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life, years	6 months	6 months	6 months	6 months
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life, years	2 years	2 years	2 years	2 years

Employee Benefits and Share-B55

Employee Benefits and Share-Based Compensation - Stock Option Activity (Details) - 2009 Plan [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Number of Shares
Outstanding at December 31, 2014 (in shares)			2,672
Granted (in shares)			200
Exercised (in shares)			(340)
Expired (in shares)			(2)
Forfeited (in shares)			(67)
Outstanding at June 30, 2015 (in shares)	2,463		2,463		2,672
Exercisable at June 30, 2015 (in shares)	1,425		1,425
Vested and expected to vest at June 30, 2015 (in shares)	2,435		2,435
Weighted Average Exercise Price
Outstanding at December 31, 2014 (in dollars per share)			$ 19.02
Granted (in dollars per share)			34.10
Exercised (in dollars per share)			15.54
Expired (in dollars per share)			15.57
Forfeited (in dollars per share)			23.30
Outstanding at June 30, 2015 (in dollars per share)	$ 20.60		20.60		$ 19.02
Exercisable at June 30, 2015 (in dollars per share)	16.46		16.46
Vested and expected to vest at June 30, 2015 (in dollars per share)	$ 20.50		$ 20.50
Weighted-average remaining years, outstanding (in years)			6 years 6 months		6 years 6 months
Weighted-average remaining years, exercisable at December 31, 2014 (in years)			4 years 10 months 24 days
Weighted-average remaining years, vested and expected to vest at June 30, 2015 (in years)			6 years 4 months 24 days
Aggregate Intrinsic Value, outstanding at June 30, 2015	$ 42,138		$ 42,138
Aggregate Intrinsic Value, exercisable at June 30, 2015	30,277		30,277
Aggregate Intrinsic Value, vested and expected to vest at June 30, 2015	$ 41,919		$ 41,919
Employee Stock Option [Member]
Weighted Average Exercise Price
Weighted-average fair value (in dollars per share)	$ 10.09	$ 9	$ 10.61	$ 8.29
Intrinsic value of options exercised	$ 4,300	$ 5,300	$ 6,700	$ 7,900
Unrecognized compensation cost of unvested stock options	$ 8,800		$ 8,800
Weighted average period of compensation cost recognized			2 years 8 months 12 days

Employee Benefits and Share-B56

Employee Benefits and Share-Based Compensation - Restricted Stock Activity (Details) - 2009 Plan [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Number of Shares
Outstanding at December 31, 2014 (in shares)	399
Granted (in shares)	65
Vested (in shares)	(77)
Forfeited (in shares)	(23)
Outstanding and unvested at June 30, 2015 (in shares)	364		399
Expected to vest at June 30, 2015 (in shares)	353
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 24
Granted (in dollars per share)	34.19	$ 26.46
Vested (in dollars per share)	21.57
Forfeited (in dollars per share)	22.35
Outstanding and unvested (in dollars per share)	$ 26.45		$ 24
Weighted-average remaining years, expected to vest at June 30, 2015 (in years)	1 year 3 months 18 days
Weighted-average remaining years, outstanding and unvested (in years)	1 year 3 months 18 days		1 year 6 months
Aggregate Intrinsic Value
Outstanding and unvested at June 30, 2015	$ 13,714
Expected to vest at June 30, 2015	13,329
Unrecognized compensation expense	$ 8,400
Weighted average period of compensation cost recognized	2 years 4 months 24 days
Restricted Stock Awards [Member]
Number of Shares
Outstanding at December 31, 2014 (in shares)	36
Granted (in shares)	37
Vested (in shares)	(41)
Forfeited (in shares)	(1)
Outstanding and unvested at June 30, 2015 (in shares)	31		36
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 26.47
Granted (in dollars per share)	36.05
Vested (in dollars per share)	26.47
Forfeited (in dollars per share)	27.65
Outstanding and unvested (in dollars per share)	$ 35.95		$ 26.47
Aggregate Intrinsic Value
Unrecognized compensation expense	$ 1,000
Weighted average period of compensation cost recognized	10 months 24 days

Employee Benefits and Share-B57

Employee Benefits and Share-Based Compensation - Performance Based Restricted Stock Units Activity (Details) - 2009 Plan [Member] - Performance Shares [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Number of Shares
Outstanding at December 31, 2014 (in shares)	233
Granted (in shares)	60
Vested (in shares)	(70)
Canceled (in shares)	(27)
Outstanding and unvested at June 30, 2015 (in shares)	196
Weighted-Average Grant Date Fair Value Per Share
Outstanding and unvested (in dollars per share)	$ 17.96
Granted (in dollars per share)	29.56	$ 16.49
Vested (in dollars per share)	18.91
Canceled (in dollars per share)	14.69
Outstanding and unvested (in dollars per share)	$ 21.63
Fair value of restricted stock units	$ 2.6	$ 2.1
Unrecognized compensation cost	$ 2.5
Weighted average period of compensation cost recognized	1 year 4 months 24 days

Employee Benefits and Share-B58

Employee Benefits and Share-Based Compensation - Employee Stock Purchase Plan (ESPP) Activity (Details) - Jun. 30, 2015 - 1997 Employee Stock Purchase Plan [Member] - Employee Stock Purchase Plan [Member] - USD ($) $ in Millions	Total
Share-Based Arrangements with Employees and Nonemployees [Line Items]
Unrecognized compensation cost	$ 2.2
Weighted average period of compensation cost recognized	1 month 6 days

Employee Benefits and Share-B59

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Jun. 30, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of June 30, 2015	11,052
Share options outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of June 30, 2015	2,463
Restricted shares award outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of June 30, 2015	559
Shares authorized for future issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of June 30, 2015	4,637
ESPP shares available for future issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance as of June 30, 2015	3,393

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2015customer	Jun. 30, 2014customer	Jun. 30, 2015segmentcustomer	Jun. 30, 2014customer
Segment Reporting [Abstract]
Period of completed acquisitions			2 years
Number of segments			2
Number of reportable segments			2
Number of significant customers that accounted for more than 10% of accounts receivables | customer	0	0	0	0

Segment Information - Financial

Segment Information - Financial Performance of Reporting Segments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 112,788	$ 105,052	$ 229,009	$ 206,816
Cost of revenues	55,326	49,012	109,862	96,281
Gross profit	57,462	56,040	119,147	110,535
Operating expenses	45,038	43,482	96,344	88,023
Income from operations	12,424	12,558	22,803	22,512
Operating segments [Member]
Segment Reporting Information [Line Items]
Revenues	112,788	105,052	229,009	206,816
Cost of revenues	55,326	49,012	109,862	96,281
Gross profit	57,462	56,040	119,147	110,535
Operating expenses	31,888	30,844	66,818	60,597
Income from operations	25,574	25,196	52,329	49,938
Operating segments [Member] | Automation and Analytics [Member]
Segment Reporting Information [Line Items]
Revenues	88,701	84,702	181,480	166,201
Cost of revenues	39,403	35,992	78,255	70,932
Gross profit	49,298	48,710	103,225	95,269
Operating expenses	25,978	26,044	54,567	51,146
Income from operations	23,320	22,666	48,658	44,123
Operating segments [Member] | Medication Adherence [Member]
Segment Reporting Information [Line Items]
Revenues	24,087	20,350	47,529	40,615
Cost of revenues	15,923	13,020	31,607	25,349
Gross profit	8,164	7,330	15,922	15,266
Operating expenses	5,910	4,800	12,251	9,451
Income from operations	2,254	2,530	3,671	5,815
Corporate cost [Member]
Segment Reporting Information [Line Items]
Operating expenses	$ 13,150	$ 12,638	$ 29,526	$ 27,426